Isconova’s partner Narvac submits registration application for rabies vaccines in Russia

07/03/2011 09:37:32

Isconova’s partner NPO Narvac (”Narvac”) has submitted a registration application in Russia for Matrix M™ based rabies vaccines for dog and cat. Launch of the products on the Russian market is expected end of 2011 after which Isconova independently will prepare for launch on additional markets.

Since 2010, Isconova and Narvac, one of Russia’s leading companies in veterinary medicine, have had a strategic partnership  regarding the use of Isconova’s Matrix M™ in rabies vaccines for dog and cat for the Russian market. From sales in Russia Isconova will receive proceeds for production and from royalties, while Isconova will own all clinical data and the commercial rights for the vaccines in the rest of the world, except for China, where Isconova and Narvac will co-operate through a joint venture.

Lena Söderström, CEO of Isconova, comments;

”We have a clear ambition - to go from being a supplier to becoming a niche developer of veterinary vaccines with great medical and commercial potential. Narvac’s registration application is a milestone on the way to launch the vaccines on the Russian market and a step towards Isconova’s goal to independently launch the vaccines on additional markets.”

For more information, please contact:

Lena Söderström, CEO of Isconova
Tel 070-816 39 12, e-mail: lena.soderstrom@isconova.com

About Isconova
Isconova AB is a Swedish research and development company specialized in developing and commercializing vaccines through Isconova's patented adjuvant-technology and unique knowledge of vaccine systems. Isconova develops vaccines together with partners in the veterinary and human markets and has, since 2005, production and sales of vaccine systems on the veterinary market. Isconova’s share is traded on NASDAQ OMX First North and E. Öhman J:or AB is the company’s Certified Adviser. www.isconova.com

About Narvac
NPO Narvac is one the largest medical developers and producers of veterinary products in Russia. Narvac produces vaccines, diagnostics and therapeutics for cattle, small cattle, pigs and small animals. www.narvac.com

About Matrix M™
Matrix M™ is Isconova’s patented adjuvant for use in vaccines for humans and some animals, antibody production and immunological research.

About adjuvants
Adjuvants are substances that improve the effect and duration of vaccines.

Download PDF